Minister Ensures Strict Safety Measures in Phase 3 TB Vaccine Trial

Jakarta, Indonesianpost.com – Health Minister Budi Gunadi Sadikin assured the safety of the M72 tuberculosis vaccine following successful completion of the first phase of clinical trials. The vaccine is currently undergoing phase 3 trials to assess its effectiveness.

Sadikin explained that phase 1 determined the vaccine’s safety, while phase 2 focused on human safety, and phase 3 evaluates its efficacy. Indonesia has been selected to participate in phase 3, with over 2,000 doses already administered.

Read Also: Minister Hails Pope Leo XIV’s Inaugural Call for Peace

The clinical trials, conducted by the University of Indonesia and Padjajaran University, are expected to help the vaccine’s global launch by 2029. Sadikin emphasized Indonesia’s critical role in TB vaccine development, given its high tuberculosis-related mortality rate. He stressed that participation would secure priority access to vaccine production.

With 2,095 participants enrolled, the phase 3 trial is being conducted alongside studies in South Africa, Kenya, Zambia, and Malawi, and is supported by the Gates Foundation. The trials are being monitored by WHO, BPOM, the Ministry of Health, and international TB experts. (BL/ANTARA)